Evidence-based personas put behaviour at the centre of customer intelligence

Tern plc

Personas are useful when they help a business understand how people think, decide and act. They are less useful when they simply create a polished version of what a customer might say. That distinction is becoming more important as artificial intelligence makes it easier to generate convincing customer profiles at speed.

Synthetic personas can appear highly realistic. They can answer questions, react to messages and simulate preferences. This makes them useful for quick testing, creative development and early exploration. The risk is that they may reflect what a model assumes a person would say rather than what real people are likely to do.

Evidence-based personas take a different approach. They are built from real-life data and behavioural signals, with synthetic data used to improve and optimise the model. This matters because commercial decisions need more than plausible language. They need insight into behaviour, timing, barriers, motivations and likely action.

Synthetic personas focus mainly on what people say. Evidence-based personas focus on what people do. That makes them more relevant when decisions carry greater risk, when audiences are complex, or when timing matters. In sectors such as healthcare and life sciences, where customer behaviour can be shaped by regulation, professional context and patient need, a stronger evidence base can improve the quality of decision-making.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Search